Aminopromazine hydrochloride | 1236-82-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: Aminopromazine hydrochloride
• 英文别名: 10-[2,3-bis(dimethylamino)propyl]phenothiazine hydrochloride；1-N,1-N,2-N,2-N-tetramethyl-3-phenothiazin-10-ylpropane-1,2-diamine;hydrochloride
• CAS: 1236-82-4
• 化学式: C₁₉H₂₅N₃S*ClH
• 分子量: 363.955
• InChiKey: ISZDANQLTTVSKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  35
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Combination therapy for the treatment of immunoinflammatory disorders
  申请人：——

  公开号：US20040224876A1

  公开（公告）日：2004-11-11

  The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a non-steroidal immunophilin-dependent immunosuppressant (NsIDI) and an NsIDI enhancer (NsIDIE) or analog or metabolite thereof to the patient. The invention also features a pharmaceutical composition containing an NsIDI and NsIDIE or analog or metabolite thereof for the treatment or prevention of an immunoinflammatory disorder.

  本发明的特点是通过向患者施用非甾体类免疫嗜血素依赖性免疫抑制剂（NsIDI）和NsIDI增强剂（NsIDIE）或其类似物或代谢物来治疗被诊断患有或有可能患上免疫炎症性疾病的患者。本发明还具有一种含有 NsIDI 和 NsIDIE 或其类似物或代谢物的药物组合物，用于治疗或预防免疫炎症性疾病。
• COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS
  申请人：CombinatoRx, Incorporated

  公开号：EP1599212A2

  公开（公告）日：2005-11-30
• EP1599212A4
  申请人：——

  公开号：EP1599212A4

  公开（公告）日：2006-02-08
• Soft tissue implants and drug combination compositions, and use thereof
  申请人：Hunter L. William

  公开号：US20070196421A1

  公开（公告）日：2007-08-23

  Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring drug combination in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
• Anti-scarring drug combinations and use thereof
  申请人：Hunter L. William

  公开号：US20070208134A1

  公开（公告）日：2007-09-06

  The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.